{"nctId":"NCT00403767","briefTitle":"An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation","startDateStruct":{"date":"2006-12"},"conditions":["Atrial Fibrillation","Stroke","Embolism"],"count":14269,"armGroups":[{"label":"Rivaroxaban","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban","Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo)"]},{"label":"Warfarin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Warfarin","Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo)"]}],"interventions":[{"name":"Rivaroxaban","otherNames":[]},{"name":"Warfarin","otherNames":[]},{"name":"Matching placebo for Rivaroxaban arm (Warfarin placebo)","otherNames":[]},{"name":"Matching placebo for Warfarin arm (Rivaroxaban placebo)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have documented atrial fibrillation on 2 separate occasions within 6 months before screening\n* History of a prior stroke, transient ischemic attack or non-neurologic systemic embolism believed to be cardiac in origin, or at least two of the following risk factors: heart failure, hypertension, age 75 years or greater, diabetes mellitus\n\nExclusion Criteria:\n\n* Significant mitral stenosis\n* Transient atrial fibrillation caused by a reversible disorder\n* Active internal bleeding\n* Severe disabling stroke\n* History of intracranial bleeding\n* Hemorrhagic disorders","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority)","description":"The number of patients with the first occurrence of a stroke or non-CNS systemic embolism while on treatment (defined as the time interval from the first dose to the last dose of study drug plus 2 days). The statistical analysis is based on time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"241","spread":null}]}]}]},{"type":"PRIMARY","title":"The Composite of Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Superiority)","description":"The number of patients with the first occurrence of a stroke or non-CNS systemic embolism while on treatment (defined as the time interval from the first dose to the last dose of study drug plus 2 days). The statistical analysis is based on time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"243","spread":null}]}]}]},{"type":"PRIMARY","title":"The Composite Event of Major/Non-major Clinically Relevant Bleeding Events: Primary Safety","description":"The number of patients with the first occurrence of a major or non-major clinically relevant bleeding event while on treatment. The statistical analysis is based on time from the first dose of study drug to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1475","spread":null},{"groupId":"OG001","value":"1449","spread":null}]}]}]},{"type":"SECONDARY","title":"The Composite Event of Stroke/Non-CNS Systemic Embolism/Vascular Death","description":"The number of patients with the first occurrence of a stroke, non-CNS systemic embolism, or vascular death while on treatment. The statistical analysis is based on time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"346","spread":null},{"groupId":"OG001","value":"410","spread":null}]}]}]},{"type":"SECONDARY","title":"The Composite Event of Stroke/Non-CNS Systemic Embolism/Myocardial Infarction/Vascular Death","description":"The number of patients with the first occurrence of a stroke, non-CNS systemic embolism, myocardial infarction, or vascular death while on treatment. The statistical analysis is based on time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"433","spread":null},{"groupId":"OG001","value":"519","spread":null}]}]}]},{"type":"SECONDARY","title":"The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Stroke","description":"The number of patients with the first occurrence of a stroke while on treatment. The statistical analysis is based on time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"221","spread":null}]}]}]},{"type":"SECONDARY","title":"The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Non-CNS Systemic Embolism","description":"The number of patients with the first occurrence of a non-CNS systemic embolism while on treatment. The statistical analysis is based on time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Myocardial Infarction","description":"The number of patients with the first occurrence of a myocardial infarction while on treatment. The statistical analysis is based on time from randomization to the first occurrence of the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]}]},{"type":"SECONDARY","title":"The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Vascular Death","description":"The number of patients with the occurrence of vascular death while on treatment. The statistical analysis is based on time from randomization to the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality","description":"The number of patients who died due to any cause while on treatment. The statistical analysis is based on time from randomization to the event while on treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"208","spread":null},{"groupId":"OG001","value":"250","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2649,"n":7111},"commonTop":["Epistaxis","Dizziness","Oedema Peripheral","Nasopharyngitis","Diarrhoea"]}}}